论文信息 - Reply from Authors re: Robert J. Hamilton, Gerald L. Andriole, Stephen J. Freedland. 5α-Reductase Inhibitors: Preventing the Treatable. Eur Urol 2012;62:242–4 - 字舞流文

Reply from Authors re: Robert J. Hamilton, Gerald L. Andriole, Stephen J. Freedland. 5α-Reductase Inhibitors: Preventing the Treatable. Eur Urol 2012;62:242–4

K. Messer | I. Thompson | A. Kristal | J. Schenk | J. Parsons | K. Arnold | C. Till | Karen Messer | I. Thompson | Kathryn B. Arnold

[1] G. Andriole,et al. 5α-reductase inhibitors: preventing the treatable. , 2012, European urology.

[2] K. Messer,et al. Finasteride reduces the risk of incident clinical benign prostatic hyperplasia. , 2012, European urology.

[3] M. Kuskowski,et al. Complications of Foley catheters--is infection the greatest risk? , 2012, The Journal of urology.

[4] D. Tindall,et al. Effect of dutasteride on the risk of prostate cancer. , 2010, The New England journal of medicine.

[5] J. K. Parsons,et al. Lower urinary tract symptoms increase the risk of falls in older men , 2009, BJU international.

[6] T. Wilt,et al. Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7] K. Messer,et al. Incidence and prevention of iatrogenic urethral injuries. , 2008, The Journal of urology.

[8] M. Kattan,et al. Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. , 2007, Journal of the National Cancer Institute.

[9] Michael M Lieber,et al. The influence of finasteride on the development of prostate cancer. , 2003, The New England journal of medicine.